Intended for healthcare professionals

Letters Age related macular degeneration

Cost comparison of ranibizumab and bevacizumab

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d5058 (Published 23 August 2011) Cite this as: BMJ 2011;343:d5058
  1. Timothy L Jackson, Higher Education Funding Council for England senior clinical lecturer and honorary consultant ophthalmic surgeon1,
  2. Lucy Kirkpatrick, trial facilitator, research office1
  1. 1Department of Ophthalmology, King’s College Hospital, London SE5 9RS, UK
  1. t.jackson1{at}nhs.net

Wet age related macular degeneration (AMD) is the leading cause of blindness in the UK.1 Most UK patients are treated with ranibizumab (Lucentis, Novartis), according to National Institute for Health and Clinical Excellence (NICE) guidance. The NHS pays for the first 14 injections; thereafter, the cost is reimbursed by Novartis, but the NHS still spent £138m (€159m; $225m) on ranibizumab in 2010.2

The CATT trial reported that bevacizumab produced an equivalent visual outcome but cost $385 per patient per year …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription